Editas Medicine, Inc. (LON:0IFK)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 299.26M +32.8% |
| Revenue (ttm) | 35.43M +20.8% |
| Net Income | -55.74M |
| EPS | -0.55 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,848 |
| Open | 2.620 |
| Previous Close | 2.680 |
| Day's Range | 2.610 - 2.780 |
| 52-Week Range | 1.671 - 4.530 |
| Beta | 2.09 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 3, 2026 |
About Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated ... [Read more]
Financial Performance
In 2025, Editas Medicine's revenue was $40.52 million, an increase of 25.39% compared to the previous year's $32.31 million. Losses were -$160.06 million, -32.49% less than in 2024.
Financial numbers in USD Financial StatementsNews
Editas slips amid pressure on gene-editing sector after Anthropic update
Editas Medicine (EDIT) is trading lower alongside other gene editing peers after Anthropic shared early findings on a CRISPR like enzyme system. Anthropic said its Claude model autonomously identified...
Editas Medicine upgraded to Buy at Guggenheim on EDIT-401 potential
As previously reported, Guggenheim upgraded Editas Medicine (EDIT) to Buy from Neutral with a $5 price target Should clinical data confirm EDIT-401’s preclinical efficacy with acceptable safety, the f...
Editas Medicine upgraded to Buy from Neutral at Guggenheim
Guggenheim upgraded Editas Medicine (EDIT) to Buy from Neutral with a $5 price target
Editas Medicine Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The company has fully pivoted to in vivo CRISPR therapeutics, with EDIT-401 targeting a 90% LDL cholesterol reduction and first patient dosing expected this year. Key clinical milestones include safety data in Q1 next year and top-line results in 2027, supported by a strong cash position into 2028.
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced t...
Editas Medicine Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is advancing in vivo CRISPR therapies, with EDIT-401 targeting severe hypercholesterolemia by upregulating LDL receptors. Phase I trials will start in Australia this year, with safety data expected in Q1 2027 and U.S. entry planned for 2027. Cash runway extends into 2028.
Editas Medicine appoints Dan Ory as chief medical officer
Editas Medicine (EDIT) announced the appointment of Dan Ory as chief medical officer, effective immediately. Ory will oversee the company’s clinical development strategy and operations as Editas advan...
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...
Editas Medicine files $400M mixed securities shelf
16:27 EDT Editas Medicine (EDIT) files $400M mixed securities shelf
Editas Medicine Registration statement: Registration filing
Editas Medicine filed a registration statement on August 31, 2026, providing details about a securities offering with the SEC.
Editas Medicine initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Editas Medicine (EDIT) with a Buy rating and $6 price target
Editas Medicine reports Q2 EPS (15c), consensus (28c)
Reports Q2 revenue $11.89M, consensus $2.75M. The revenue increase was primarily attributable to the recognition of deferred revenue related to the expiration certain rights to opt-in to additional re...
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, incl...
Editas Medicine Earnings release: Q2 2026
Editas Medicine released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Editas Medicine Quarterly report: Q2 2026
Editas Medicine has published its Q2 2026 quarterly earnings report on August 5, 2026.
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D.
Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 t...
Editas Medicine Transcript: AGM 2026
The meeting covered director elections, executive compensation, and auditor ratification, all of which passed. Strategic updates focused on EDIT-401's clinical progress and a major public offering to fund development. No questions were raised by stockholders during the session.
Editas Medicine Transcript: Jefferies Global Healthcare Conference 2026
A novel CRISPR-based therapy, EDIT-401, demonstrated durable 90% reductions in LDL cholesterol and Lp(a) in preclinical studies, targeting high-risk cardiovascular patients. Clinical trials are set to begin in Australia in 2024, with top-line data expected in 2027.
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today an...
Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI
After Editas Medicine (EDIT) presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral presentation at the European Atherosclerosis Society Congress, Evercore ISI...
TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’
TD Cowen notes that Editas Medicine (EDIT) presented “compelling preclinical data” at EAS detailing EDIT-401’s 90% reduction in low-density lipoprotein cholesterol, apolipoprotein B and lipoprotein(a)...
Editas Medicine 55.6M share Secondary priced at $2.25
Cantor Fitzgerald and Wells Fargo acted as joint book running managers for the offering.
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the...